A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 5, 2009, Pages 945-952

  Graham, Janet S ^a,e   Falk, Stephen ^b   Samuel, Leslie M ^c   Cendros, Josep M ^d   Evans, T R Jeffry ^a  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^c ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^d IPSEN   (France)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

CYP3A4; Diflomotecan; Homocamptothecins; Pharmacokinetics; Topoisomerase 1

Indexed keywords

CYTOCHROME P450 3A4; DIFLOMOTECAN; DRUG METABOLITE; ERYTHROMYCIN;

ADULT; ADVANCED CANCER; AGED; ANAPHYLAXIS; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BREATH ANALYSIS; CHOLANGITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS CANCER; FATIGUE; FEMALE; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; PRIORITY JOURNAL; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA; THRUSH;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; BREATH TESTS; CAMPTOTHECIN; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROMYCIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TISSUE DISTRIBUTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 61449216100     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0795-6     Document Type: Article

References (22)

1. ME Wall MC Wani CE Cook KH Palmer 1966 Plant antitumor agents, I: the isolation and structure of camptothecin, a novel alkaloidal leukaemia and tumor inhibitor from Camptotheca acuminate J Am Chem Soc 88 3888 3890
2. YH Hsiang 1985 Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I J Biol Chem 260 27 14873 14878
3. YH Hsiang LF Liu 1988 Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin Cancer Res 48 7 1722 1726
4. BC Giovanella 1989 DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts Science 246 4933 1046 1048
5. HL McLeod 1994 Topoisomerase I and II activity in human breast, cervix, lung and colon cancer Int J Cancer 59 5 607 611
6. PJ Creaven LM Allen 1973 Renal clearance of camptothecin (NSC-100880): effect of urine volume Cancer Chemother Rep 57 2 175 184
7. JA Gottlieb 1970 Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880) Cancer Chemother Rep 54 6 461 470
8. JF Pizzolato LB Saltz 2003 The camptothecins Lancet 361 9376 2235 2242
9. R Garcia-Carbonero JG Supko 2002 Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins Clin Cancer Res 8 3 641 661
10. L Lesueur-Ginot 1999 Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties Cancer Res 59 12 2939 2943
11. C Bailly 1999 Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks Biochemistry 38 47 15556 15563
12. IF Troconiz 2006 Phase I dose-finding study and a pharmacokinetic/ pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours Cancer Chemother Pharmacol 57 6 727 735
13. L Scott 2007 A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours Ann Oncol 18 3 569 575
14. H Gelderblom 2003 Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors Clin Cancer Res 9 11 4101 4107
15. N Osheroff 2004 Diflomotecan. Ipsen IDrugs 7 3 257 263
16. P Therasse 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 205 216
17. RH Mathijssen 2002 Impact of body-size measures on irinotecan clearance: alternative dosing recommendations J Clin Oncol 20 1 81 87
18. Bonneterre J, Cottu P, Adenis A et al (2000) First results of a phase I trial of BN-80915 administered intraenously in patients with advanced malignant tumors. Clin Cancer Res 6(4513s abs 234)
19. PB Watkins 1994 Noninvasive tests of CYP3A enzymes Pharmacogenetics 4 4 171 184
20. PB Watkins 1989 Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients J Clin Invest 83 2 688 697
21. LP Rivory 2000 Optimizing the erythromycin breath test for use in cancer patients Clin Cancer Res 6 9 3480 3485
22. A Sparreboom 2004 Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype Clin Pharmacol Ther 76 1 38 44